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Abstract
Background—The neuropeptides orexin A and B play a role in reward and feeding and are 
critical for arousal. However, it was not initially appreciated that most prepro-orexin synthesizing 
neurons are almost exclusively concentrated in the perifornical hypothalamus, which when 
stimulated elicits panic-associated behavior and cardiovascular responses in rodents and self-
reported “panic attacks” and “fear of dying” in humans. More recent studies support a role for the 
orexin system in coordinating an integrative stress response. For instance, orexin neurons are 
highly reactive to anxiogenic stimuli, are hyperactive in anxiety pathology, and have strong 
projections to anxiety and panic-associated circuitry. Although the two cognate orexin receptors 
are colocalized in many brain regions, the orexin 2 receptor (OX2R) most robustly maps to the 
histaminergic wake-promoting region, while the orexin 1 receptor (OX1R) distribution is more 
exclusive and dense in anxiety and panic circuitry regions, such as the locus ceruleus. Overall, this 
suggests that OX1Rs play a critical role in mobilizing anxiety and panic responses.
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Methods—Here, we used a CO2-panic provocation model to screen a dual OX1/2R antagonist 
(DORA-12) to globally inhibit orexin activity, then a highly selective OX1R antagonist (SORA1, 
Compound 56) or OX2R antagonist (SORA2, JnJ10397049) to assess OX1R and OX2R 
involvement.
Results—All compounds except the SORA2 attenuated CO2-induced anxiety-like behaviors, and 
all but the SORA2 and DORA attenuated CO2-induced cardiovascular responses.
Conclusions—SORA1s may represent a novel method of treating anxiety disorders, with no 
apparent sedative effects that were present with a benzodiazepine.
Keywords
hypercapnia; panic; anxiety; orexin; hypocretin; hypothalamus; chemoreception; COPD; 
bronchitis; asthma
INTRODUCTION
Panic, fear, and anxiety states are adaptive responses to cope with an immediate imminent 
threat, potential imminent threat, or a nonimminent threat (e.g., distal or temporal), 
respectively. Responses consist of an integrated pattern of behaviors such as fleeing or 
fighting during panic, vigilance or freezing during fear, and avoidance during anxiety states. 
Panic- and fear-associated behaviors are also strongly associated with robust cardiovascular 
and respiratory responses. In the 1940s, Hess and Brugger found a panic-generating site in 
the perifornical hypothalamic region (PeF) of cats where electrical stimulation produced 
strong behavioral and autonomic responses resembling panic/defense reactions (e.g., 
increased blood pressure, piloerection, hissing, and arching of back).[1] Such responses are 
mirrored in rodents.[2–6] Furthermore, stimulating the PeF region in humans produces self-
reports of panic and fear of dying that are accompanied by panic- and fear-associated 
autonomic responses (e.g., tachycardia, increased blood pressure, hyperventilation, thermal 
sensations, and paresthesias);[7–9] all symptoms associated with panic attacks (PAs) in 
patients with panic disorder (PD).[10] Chronic disinhibition of the PeF also produces rats that 
are vulnerable to displaying panic-like responses to interoceptive stimuli, such as 
hypercapnia (elevated blood pCO2), that signals suffocation (see review[11]) and provokes 
PAs in subjects with PD.[12–14] This region has only recently gained further attention in the 
context of arousal, anxiety, fear, and panic with the discovery of orexin (OX) neurons in 
1998.[15,16] These neurons are almost exclusively localized within the PeF and adjacent 
lateral hypothalamus of rodents[17] and humans,[18] and are critical for arousal.[19]
Orexin’s role in more complex emotional responses is evolving, and recent studies have 
demonstrated that orexin neurons are highly responsive to anxiogenic stimuli; strongly 
innervate anxiety and panic-associated neural systems; and are involved in mobilizing an 
adaptive, integrated stress response [see reviews[20,21]]. Additionally, we recently 
determined that this system plays a critical role in coordinating panic-associated anxiety and 
cardiovascular responses in a panic vulnerability model, and neuropsychiatric patients with 
increased anxiety symptoms had elevated cerebrospinal fluid orexin levels.[22] Subsequent 
studies have determined that optogenetically stimulating orexin neurons in rats increase 
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anxiety states and activity in anxiety-related neural circuits,[23] and the orexin system is also 
implicated in fear-associated learning.[24–26]
Orexins (OXA and OXB) are derived from a common precursor, prepro-orexin, and have 
high sequency homology; human and rat forms of OXA are 100% conserved.[16] There are 
two cognate G-protein coupled receptors for orexins that are colocalized in many brain 
regions, but the orexin 2 receptor (OX2R) is most dominantly located in wake-promoting 
systems (e.g., histaminergic system). In contrast, the orexin 1 receptor (OX1R) is almost 
exclusively expressed in vigilance and anxiety/fear/panic regions, such as the locus ceruleus 
(LC). Moreover, the OX1 to OX2 expression ratio is also higher in the panic, fear, and 
anxiety-associated circuitry, such as the bed nucleus of the stria terminalis BNST, amygdala, 
and anterior cingulate.[27,28] Important with respect to translational studies, conservation 
between rat and human OX1R and OX2R is very high—94 and 95%, respectively.[16] 
Overall, these studies suggest that selective OX1R antagonists (SORA1) may represent a 
novel method of treating anxiety.
Consistent with this hypothesis is that systemically administering the centrally active 
SORA1 SB334867[29] attenuates panic-associated responses following panicogenic 
challenges (e.g., “suffocation”-associated stimuli (CO2),[30] sodium lactate,[22] and 
anxiogenic drugs[31]). However, there are concerns that SB334867 is hydrolytically 
unstable[32] and has off target effects at higher concentrations (unpublished results in 
review[33]).
Therefore, in the present series of studies, we used a 20% CO2-panic provocation model to 
screen highly selective and well-characterized orexin receptor antagonists (i.e., a dual 
OX1/2r antagonist [DORA-12] to globally inhibit orexin activity; then a highly selective 
SORA1 (Compound 56) and SORA2 (JnJ10397049) to assess OX1r and OX2r involvement) 
alongside a benzodiazepine positive control for panicolytic properties. In rats, the 20% CO2-
induced panic provocation produces anxiety and fear-associated behaviors, and marked 
cardiovascular and thermoregulatory responses associated with panic states,[30,34,35] 
replicating a similar 20% CO2-provocation model used in healthy humans that evokes 
symptoms consistent with criteria for PAs.[36]
MATERIALS AND METHODS
ANIMALS AND HOUSING CONDITIONS
Adult male Sprague-Dawley rats (300–350 g, Harlan Laboratories, Indianapolis, IN) were 
housed individually under standard environmental conditions (22°C; 12-h light:12-hdark 
cycle; lights on at 7:00 a.m.) for 5–7 days prior to the surgical manipulations. Food and 
water were provided ad libitum. Animal care procedures were conducted in accordance with 
the NIH Guidelines for the Care and Use of Laboratory Animals, 8th Edition and the 
guidelines of the IUPUI Institutional Animal Care and Use Committee.
Telemetry Probe Implantation—Prior to and during surgery, rats were anesthetized 
with isoflurane (MGX Research Machine; Vetamic, Rossville, IN), then had a radio-
telemetric probe (Model. HD-S11, Data Sciences International, St. Paul, MN) implanted into 
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the peritoneal cavity and a pressure transducer implanted into the femoral artery as described 
previously,[30] which can simultaneously measure mean arterial blood pressure (MAP), 
heart rate (HR), core body temperature (CBT), and general locomotor activity in freely 
moving rats.
Description of Hypercarbic or Atmospheric Gas Infusions and Drug Treatment 
Protocol—We previously used CO2 (ProCO2) and O2 (ProO2) sensors in our enclosed 
flow cages (12″ width × 12″ height × 24″ length) and verified that O2 and CO2 
concentrations remain normal with atmospheric air infusion, and only the CO2 
concentrations rapidly increase from <1 to 20% at the 5-min time point for CO2 
challenge.[37] In a counter-balanced design (i.e., all rats receive each drug treatment with at 
least 48 hr between treatments), rats were systemically treated with a control vehicle or 
different doses of compounds, then placed into the chamber where atmospheric air was 
being infused. All rats had infusions of the following: (1) 5 min infusion of atmospheric gas 
(<1% CO2, 21% O2, 79% N2: Praxair, Inc., Indianapolis, IN) for baseline measurements 
(approximately 45–60 min posttreatment), then (2) either the control gas or experimental 
normoxic, hypercarbic gas (20% CO2, 21% O2, 59% N2: Praxair) for 5 min (note: for 
control rats the atmospheric gas was turned off and back on again at the beginning and end 
of this infusion to be identical to the manipulations for the hypercarbic gas challenge), and 
finally, (3) 5 min infusion of atmospheric gas. Following exposure to hypercarbic and 
atmospheric air gases, rats were immediately placed in the open field box for 5 min, then 
assessed in a social interaction (SI) test for 5 min. The data reported are changes in activity, 
expressed in 1 min bins, relative to the average of the baseline measurement (t − 5 min to t − 
1 min) from each rat.
SI and Open Field Behavioral Testing—The open field arena is 90 cm × 90 cm, with 
40 cm walls, and divided into a 6 × 6 grid of equally sized squares. Four squares form the 
center, and constitute the starting position of the test.
The SI test was done in the open field arena and is a fully validated test of experimental 
anxiety-like behavior in rats.[38,39] The “experimental” rat and an unfamiliar “partner” rat 
are both placed in the center of the box, and the total duration (second) of nonaggressive 
physical contact (grooming, sniffing, crawling over and under, etc.) initiated by the 
“experimental” rat is quantified over 5 min. All behaviors were videotaped, and sessions 
were scored using ANY-maze (Stoelting, Wood Dale, IL) for open field (Stoelting), or by 
Stephanie D. Fitz (whom was blind to treatments) for SI.
Experiment 1–2: Effects of High and Low Doses of Lorazepam on CO2 
Induced Responses—In the first experiment, rats were injected intraperitoneal (i.p.) 
with a control vehicle (0.2 ml/100 g volume dimethyl sulfoxide [DMSO]) or one of two 
higher doses of the benzodiazepine lorazepam (0.5 or 1 mg/kg, laboratory animal resource 
center LARC). In a second experiment, rats were injected i.p. with a control vehicle (0.2 
ml/100 g volume DMSO) or one of two lower doses of the benzodiazepine lorazepam (0.1 
or 0.3 mg/kg).
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Experiment 3: Effects of DORA-12 on CO2-Induced Responses—Five days prior 
to experiments, rats were trained with a mock gavage. On the experimental day, rats 
received an oral gavage of a control vehicle (0.2 ml/100 g volume 20% vitamin E/TPGS) or 
30 mg/kg of a dual orexin 1/2 receptor antagonist, DORA-12 (Merck & Co.) with balanced 
potency for OX1R (Ki = 1.8 nM, FLIPR IC50 = 27 nM) and OX2R (Ki = 0.17 nM, 
FLIPRIC50 = 27 nM) and good brain exposure (passive permeability of 38 × 10−6 cm/s and 
Pgp efflux of 0.6 (BA/AB), 47% oral bioavailability, and a favorable brain to plasma ratio of 
0.4–0.6.[40,41] This compound is a close structural analogue of suvorexant, and the 30 mg/kg 
PO dose of DORA-12 used here achieves a plasma Cmax of 2.02 μM with CSF exposure of 
66 nM and ex vivo occupancy of 97%, and has been shown to promote sleep in rats.[40,42]
Experiment 4: Effects of SB334867 on CO2-Induced Responses—All rats were 
injected i.p. with a control vehicle (0.2 ml/100 g volume DMSO) or a 30 mg/kg dose of 
SB334867 (Tocris Bioscience, in 0.2 ml/100 g volume DMSO, i.p.) which has selectivity of 
50× for the OX1 receptor compared to the OX2R[33] and attenuates stress-induced anxiety-
like behavior and panic-associated cardioexcitatory responses without inducing somnolence 
in the CO2 model described here.[30] Subcutaneous administration of this SORA1 crosses 
the blood–brain barrier, and in an ex vivo receptor-binding assay of a brain region with high 
expression of OX1Rs, a 10 mg/kg dose occupies approximately 80% of OX1Rs 30–60 min 
postinjection, and a 30mg/kg dose displays almost 100% occupancy of OX1Rs.[43]
Experiment 5: Effects of Compound 56 on CO2-Induced Responses—All rats 
were injected subcutaneous (s.c.) with a control vehicle (0.2 ml/100 g volume DMSO) or 
one of three doses of the highly SORA1 Compound 56 (either 3, 10, or 30 mg/kg (N-({3-
[(3-ethoxy-6-methylpyridin-2-yl)carbonyl]-3-azabicyclo[4.1.0]hept-4-ylmethyl)-5-
(trifluoromethyl)pyrimidin-2-amine),[44] which has 44× selectivity for the OX1 receptor 
compared to the OX2 receptor.[43] Subcutaneous administration of this SORA1 crosses the 
blood–brain barrier, and in an ex vivo receptor binding assay of a brain region with high 
expression of OX1Rs, a 10 mg/kg dose occupies approximately >90% of OX1Rs 30–60 min 
postinjection.[43] Unlike SB334867, which has been shown to have off-target affinities for 
non-OXRs,[33] in a binding assay panel of 50 receptors, ion channels, and transporters, 
Compound 56 did not exhibit a significant affinity to anything other than the OX1R.[43]
Experiment 6: Effects of JnJ10397049 on CO2-Induced Responses—All rats 
were injected s.c. with a control vehicle (0.2 ml of 10% pharmasolve, 5% solutol, and 85% 
dextrose in water) or a dose of JnJ10397049 (10 or 30 mg/kg, Tocris Biosciences, in 0.2 ml) 
which has 630× selectivity for the OX2R compared to the OX1R.[33] Subcutaneous 
administration of this SORA2 crosses the blood–brain barrier, and in an ex vivo receptor-
binding assay of a brain region with high expression of OX2Rs and OX1Rs, a 30mg/kg dose 
occupies approximately 75–80% of OX2Rs, but does not bind to OX1Rs, 30—60 min 
postinjection.[45]
Experiment 7: Effects of Repeated Hypercarbic Gas Exposure on Behavior 
and Physiology—Since all of the above experiments were done in a crossover design, a 
group of six rats were implanted with radiotelemetry probes and exposed to 20% CO2, 
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normoxic air, as described previously, on day 1, day 3, and day 5 to confirm that repeated 
20% CO2, normoxic gas exposure did not result in exacerbated or diminished anxiety or 
physiological responses.
STATISTICAL ANALYSES
For experiments 1–7, dependent variables for analyses of open field and SI behaviors, 
cardiovascular (HR, MAP), locomotor activity, and CBT were analyzed using an ANOVA 
with drug/gas as main factor and, additionally, time as a repeated measures for physiological 
parameters. In the presence of significant main effects or main effect × time interactions, 
Fisher’s least significant difference (LSD), protected by ANOVAs at each time point (when 
relevant), was used for post hoc analyses. The alpha level was set at 0.05.
RESULTS
EXPERIMENT 1–2: EFFECTS OF HIGH AND LOW DOSES OF LORAZEPAM ON CO2-
INDUCED RESPONSES
In experiment 1, lorazepam blocked CO2-induced pressor responses (F(42,378) = 4.8, P < .
001, n = 8, 7, 8, 8, Fig. 1a). One CO2/Veh rat was removed due=to a series of MAP that 
were more than two standard deviations from the mean. The high dose attenuated the onset 
of the CO2-induced bradycardia (F(42,392) = 18.5, P < .001, n = 8/group, Fig. 1b). For 
locomotor activity, the CO2-induced increase was reduced at both doses (F(42,392) = 2.6., P 
= 0.017, n = 8/group, Fig. 1d, n = 8/group). However, locomotor activity was reduced prior 
to gas challenges and potentially indicates a sedative effect (F(3,31) = 6.5, P = 0.002, see bar 
graph inset to top right). Lorazepam attenuated the CO2-induced decrease in CBT (F(14,80) = 
23.7, P < .001, n = 6/group, Fig. 1e). For CBT, two rats were removed due to consistently 
nonphysiological CBT. There were no differences noted at baseline between treatment 
groups for MAP, HR, or CBT.
CO2 reduced SI behaviors (F(3,28) = 10.8, P < .001, n = 8/group, Fig. 1c). However, the 
highest dose of lorazepam decreased the SI time further. Given that locomotor activity was 
decreased prior to gas challenges (Fig. 1d inset), these data suggest that lorazepam was 
sedative. In the open field test, the highest dose of lorazepam decreased line crossing (F(3,28) 
= 3.9, P = .019, Fig. 1f), which is another indication of a potential sedative effect. There 
were no differences in center time (F(3,28) = 0.5, P = .655, Fig. 1f).
In light of potential sedative effects and no detected anxiolytic effect of lorazepam, 
experiment 2 was conducted with lower doses. Here, lorazepam did not alter CO2-induced 
pressor responses (F(28,252) = 1.2, P = .223, n = 7/group, Fig. 2a), and the 0.3 mg/kg dose of 
lorazepam attenuated the CO2-induced bradycardia at one time point (F(28,252) = 1.5, P = .
047, Fig. 2b). Lorazepam did not alter baseline locomotor activity over time (F(2,18) = 1.0, P 
= .395), and there were no overall treatment effects (F(28,252) = 1.1., P = .323, Fig. 2d). CO2-
induced drops in CBT (F(28,252) = 3.0, P <.001) were attenuated with the 0.3 mg/kg dose of 
lorazepam (Fig. 2e). No significant baseline differences were noted for MAP, HR, or CBT.
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Both doses of lorazepam increased SI behaviors (F(2,18) = 4.3, P = .030, n = 7/group, Fig. 
2c). In the open field test, there was no effect on line crossing (F(2,18) = .3, P = .737, n = 7/
group) or center time (F(2,18) = 0.1, P = .865, n = 7/group, Fig. 2f).
EXPERIMENT 3: EFFECTS OF DORA-12 ON CO2-INDUCED RESPONSES
A robust CO2-induced pressor (F(28,336) = 7.0, P < .001, n = 9/group, Fig. 3a) and 
bradycardia (F(28,336) = 20.0, P < .001, n = 9/group, Fig. 3b) response was not attenuated by 
DORA-12. The increase in locomotor activity following CO2 was not altered by DORA-12 
(F(28,336) = 3.3, P < .001, Fig. 3d). There were differences noted at baseline (F(2,24) = 9.4, P 
< .001), where the veh/CO2 and DORA-12/CO2 group has lower baseline activity (see table 
of baseline data in Fig. 3d) than the veh/atm. air group that had abnormally high baseline 
activity. For CBT, a robust CO2-induced response was not altered by DORA-12 (F(28,336) = 
28.5, P < .001, n = 9/group, Fig. 3e). There were no significant baseline differences noted 
for MAP, HR, or CBT.
The CO2-induced reduction in SI behaviors (indicating anxiety state) were attenuated by 
DORA-12 (F(2,27) = 6.5, P = .005, n = 10/group, one probe malfunctioned so there is an n = 
9/group for telemetry, Fig. 3c). In the open field test, there was no effect detected for line 
crossing (F(2,27) = 0.4, P = .641) or center time (F(2,27) = 2.8, P = .078, Fig. 3f).
EXPERIMENT 4: EFFECTS OF SB334867 ON CO2-INDUCED RESPONSES
SB334867 attenuated CO2-induced pressor responses (F(28,266) = 8.5, P < .001, n = 8,7,7, 
Fig. 4a), but did not significantly alter CO2-induced bradycardia responses at any time point 
(CO2 effect, F(28,266) = 18.5., P < .001, Fig. 4b). For locomotor activity, the SB334867/CO2 
group was significantly higher at one time point than the vehicle/CO2 group (F(28,266) = 1.7., 
P = .020, Fig. 4d). SB334867 significantly attenuated the CO2-induced decrease in CBT 
(F(28,266) = 65.5, P < .001, Fig. 4e). There were no differences noted at baseline for MAP, 
HR, activity, or CBT. MAP, HR, and activity r values were consistently two standard 
deviations from the mean for a rat in two groups so they were removed from analyses.
The CO2-induced reduction in SI behaviors (indicating anxiety state), was blocked by 
SB334867 (F(3,31) = 4.2, P = .014, n = 8/group, Fig 4c). In the open field test, no effect was 
seen for line crossing (F(2,21) = 0.4, P = .661) or center time (F(2,21) = 0.7, P = .495, n = 8/
group, Fig. 4f).
EXPERIMENT 5: EFFECTS OF COMPOUND 56 ON CO2-INDUCED RESPONSES
Compound 56 attenuated CO2-induced pressor responses (F(56,700) = 5.3, P < .001, n = 11/
group, Fig. 5a), and significantly altered CO2-induced bradycardia responses (F(56,700) = 
11.6., P < .001, n = 11/group, Fig. 5b). For locomotor activity, Compound 56 did not 
attenuate CO2-induced increases (CO2 effect, F(56,700) = 3.8, P < .001, n = 11/group, Fig. 
5d). Compound 56 significantly attenuated the CO2-induced decrease in CBT (F(56,700) = 
10.9, P < .001, n = 11/group, Fig. 5e). There were no differences noted at baseline for MAP, 
HR, activity, or CBT.
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The CO2-induced reduction in SI behaviors was attenuated by the 10 mg/kg dose of 
Compound 56 (F(4,50) = 12.1, P < .001, n = 11/group, Fig. 5c). In the open field test, no 
effect was noted for line crossings (F(4,50) = 1.9, P = .128, n = 11/group, Fig. 5f) or center 
time (F(4,50) = 1.1, P = .363, n = 11/group, Fig. 5f).
EXPERIMENT 6: EFFECTS OF JNJ7049 ON CO2-INDUCED RESPONSES
JnJ7049 attenuated CO2-induced pressor responses only at one time point (F(42,366) = 13.5, 
P <.001, n = 7/group, Fig. 6a), and did not significantly alter CO2-induced bradycardia (CO2 
effect, F(42,366) 11.5, P < .001, Fig. 6b). JnJ7049 did not significantly=alter CO2-induced 
locomotor activity (F(42,366) = 2.9, P < .001, Fig. 6d). JnJ7049 did not alter CO2-induced 
effects (CO2 effect, F(42,366) = 90.9, P < .001, Fig. 6e). There were no differences noted at 
baseline for MAP, HR, activity, or CBT.
The CO2-induced reduction in SI behaviors (indicating anxiety state) was not altered by 
JnJ7049 (F(3,24) = 3.9, P = .022, n = 8/group, Fig 6c). In the open field test, no effect 
was=noted on line crossings (F(3,24) = 1.7, P = .186) or center time (F(3,24) = 0.6, P = .629, 
Fig. 6f).
EXPERIMENT 7: EFFECTS OF REPEATED HYPERCARBIC GAS EXPOSURE ON BEHAVIOR 
AND PHYSIOLOGY
Repeated CO2 challenges on three different days did not alter MAP (F(30,225) = 0.5, P = .
994, n = 6,6,6, Fig. 7a), HR (F(30,225) = 1.7, P = .014, Fig. 7b), SI (F(2,15) = 0.2, P = .865, n 
= 6/day, Fig 7c), activity (F(30,225) = 0.7., P = .823, Fig. 7d), CBT (F(30,225) = 0.3, P = 1.00, 
Fig. 7e), or open field test (center time F(2,15) = 0.2, P = .802, line crossings F(2,15) = 0.5, P 
= .600, Fig. 7f) responses to CO2. There were no differences noted at baseline for MAP, HR, 
activity, or CBT.
DISCUSSION
Here, we initially determined if systemically pretreating rats with a benzodiazepine would 
attenuate panic-associated responses evoked by a 5-min exposure to 20% CO2, normoxic 
gas infusion. The initial doses were chosen based on a previous study showing that the 0.5 
mg/kg dose is anxiolytic.[46] Lorazepam blocked CO2-induced pressor response (with a 
minimal effect on bradycardia), and attenuated decreases in core temperature. However, 
these doses appeared sedative (evidenced by decreased locomotion and decreases in SI). In 
the subsequent experiment, 0.1 and 0.3 mg/kg lorazepam were used, which attenuated CO2-
induced anxiety in the SI test at both doses, and had minimal effects on autonomic and 
locomotor responses. Although benzodiazepines are currently the most effective fast-acting 
treatments for PAs;[47–49] they have significant safety concerns, including sedation, 
dependence, and addiction. Despite these issues, these data provide further validity of this 
panic provocation model by demonstrating responsiveness to an established treatment 
(postdictive validity).
We then inhibited both OX receptors with DORA-12 in the CO2 model, which attenuated 
anxiety-associated behaviors in the SI test, but did not alter CO2-induced pressor, 
bradycardia, or thermal responses. Although DORAs in general have been shown to 
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promote sleep in various species (see review in[50]), at the doses used here there were no 
obvious sedating effects noted in locomotor activity assessed with radiotelemetry or in an 
open field test.[51] Yet, soporific effects would be predicted with repeated use and in 
situations with increasing sleep pressure. Thus, globally inhibiting orexin activity with 
DORAs may be effective in treating symptoms associated with anxiety disorders with less 
somnolescent side effects as benzodiazepines.
We then assessed a highly selective SORA1 to assess OX1R involvement. Compound 56 
attenuated anxiety-associated behavior in the SI test at the highest dose and approached 
significance at a lower dose (P < .052), consistent with a previous study using 
SB334867,[30] and in an experiment replicated herein with SB334867. More importantly, 
both doses of Compound 56 also attenuated CO2-induced pressor, bradycardia, and 
hypothermic responses, without any apparent sedative effects. Although OX2R antagonists 
alone both induce and prolong sleep in rodents,[45,52] SORA1s have been shown to have 
little effect on sleep-wake states.[53] This is an important new finding and demonstrates a 
marked difference in putative clinical benefits between the SORA1 and benzodiazepines. 
These data demonstrate that at nonsedating anxiolytic doses, benzodiazepines are not 
particularly effective in blocking panic responses. Thus, to obtain panicolytic effects, 
benzodiazepines have to be taken in high doses that disrupt motor coordination and cause 
sedation. In sharp contrast to this scenario, the SORA1 appears effective in blocking panic-
associated symptoms at doses that are anxiolytic but nonsedating. This could provide the 
SORA1s a major therapeutic advantage in the treatment of PD.
In a final experiment, we screened a highly selective SORA2 (JnJ10397049) to assess 
OX2R involvement in CO2-induced panic responses. In this experiment, the SORA2 did not 
alter any panic-associated behavioral or physiological response to CO2. Similar to the 
DORA experiment, there was no obvious sedating effects noted in locomotor activity. 
Collectively, these studies suggest that the anxiolytic effects of the SORA1s (Compound 56 
and SB334867) and DORA are occurring through actions at the OX1R. Evidence in support 
of this hypothesis is that we have systemically administered less selective SORA1s (i.e., 
SB334867 and SB408124) and observed panicolytic effects in experiments using 
panicogenic challenges (e.g., “suffocation”-associated stimuli [CO2],[30] sodium lactate,[22] 
and anxiogenic/panicogenic drugs[31]). Pretreating rats with a SORA1 (SB334867) also 
attenuated cellular activation in panic/fear circuitry associated with PAs (e.g., periaqueductal 
gray, amygdala, and BNST, see reviews[54–56]) in rats challenged with the panicogenic 
compound FG-7142, a partial inverse benzodiazepine agonist.[31]
The relevance of CO2 to panic symptoms may not be immediately apparent, but subtle 
increases in CO2 in the blood (i.e., hypercapnia) that occurs from hypoventilation, or 
restricted breathing, results in acidosis in peripheral and central brain structures, which 
initially increases respiration to help “blow off” excess CO2 to prevent life-threatening 
acidosis [see review[57]]. If CO2 levels continue to rise, a feeling of “suffocation” and panic 
occurs that produces additional behaviors (e.g., urge to remove constrictive clothing, or 
escape restricted space), and physiologic responses that includes marked cardiovascular and 
thermoregulatory responses. For instance, having healthy human subjects inhale 20% CO2 
for 20 s elicits all cardinal symptoms of a PA (e.g., catastrophic fear accompanied by 
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cardiovascular and thermoregulatory responses) in 25% of subjects, and approximately 75% 
experience some significant cognitive fear or autonomic response.[36] A fairly unique 
feature of PD is that concentrations of CO2 that normally are insufficient to produce panic 
responses in healthy subjects (typically less than 5–7% CO2 concentrations) provoke PAs in 
the majority of PD subjects. Specifically, exposing PD subjects to 5% CO2 provoked a PA 
in approximately 50% of PD patients, but only increased nervousness and dyspnea in 
healthy subjects.[14] Overall, this suggests that some PAs could be provoked by subtle CO2-
related cues (pCO2, and peripheral and central acidosis), which signal suffocation. This is 
further supported from a recent meta-analysis showing that higher baseline hyperventilation 
and rates of sighing are associated with PD, and suggests that PAs may be a result of an 
overreaction to increases in arterial CO2.[58] Finally, the cardiovascular profile seen here in 
rodents with the 20% CO2 challenge (i.e., pressor and bradycardia response) appears to be 
similar to cardiovascular responses in healthy humans that have inhaled a single breath of 
35% CO2 that produces an increase in systolic blood pressure that is accompanied by a 
bradycardia and fear,[59] and this cardiovascular profile does appear during some PAs.[60]
CO2 easily crosses the blood–brain barrier to interact with central chemoreceptive 
systems.[61,62] Although there are specialized CO2/H+ chemosensory neurons that respond 
to subtle changes in CO2 that are located in respiratory medullary regions,[57] OX neurons 
have also been shown to be excited by CO2/H+,[63] and show increased cellular c-Fos 
responses to 10[64] and 20%[30] CO2, which is consistent with their involvement in CO2-
mediated panic responses. Furthermore, prepro-OX knockout mice have blunted respiratory 
responses to 5–10% hypercarbic gas exposure during wake periods, and injecting wild-type 
mice with the SORA1 SB334867 attenuates CO2-induced respiratory responses.[65] We have 
also shown that pretreating rats with SB334867 attenuates CO2-induced pressor responses 
and anxiety/fear-associated behaviors without altering respiratory responses during 
hypercarbic gas infusions.[34] This provides some additional clinical insights into subjects 
with episodes of hypercapnia (e.g., patients with chronic obstructive pulmonary disease 
(COPD), bronchitis, or asthma) who have impaired breathing that is significantly comorbid 
with severe anxiety and sympathetic arousal, which can make the management of these 
symptoms difficult. Currently, the treatment of anxiety associated with conditions such as 
COPD with traditional anxiolytics, such as benzodiazepine drugs, is unsafe due to 
significant respiratory depression, cognitive disruption, addiction, and other peripheral 
motor side effects. Therefore, SORA1s may represent a novel anxiolytic treatment for these 
respiratory conditions. Furthermore, SORA1s also reduce hypertensive responses due to 
hypercapnia, which may also be exacerbated by the use of sympathomimetics and 
bronchodilators.
Overall, the data presented here demonstrate that a 20% CO2 challenge produces consistent 
anxiety-like behaviors in the SI test and robust autonomic responses that are similar to 
physical symptoms associated with PAs. The anxiolytic effects of the benzodiazepine (used 
as a positive control) provides further postdictive validity for the 20% CO2 challenge 
increasing anxiety/panic states, and also provides further support to SORA1s and DORAs as 
potential novel anxiolytic compounds. Our data further suggest that SORA1s may be 
particularly well suited as antianxiety and antipanic agents with lower sedative properties.
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Figure 1. Line graphs indicate the effects of systemic intraperitoneal injections of 0.5 and 1 
mg/kg of the benzodiazepine lorazepam on 20% CO2-induced changes (from 5 min baseline) in 
(a) mean arterial blood pressure (MAP, mm Hg), (b) HR (beats/min, BPM), (d) general 
locomotor activity (counts/min), and decreased CBT (Celsius) in freely moving rats surgically 
implanted with radiotelemetry probes. There was no significant differences in baseline MAP, 
HR, or CBT (see legends on figures with baselines ± SEM). However, these doses of lorazepam 
did decrease general locomotor activity between groups (see bar graph inset in d). A similar 
decrease in mean behavioral activity was also observed in the (c) SI test, and (f) line crossings 
and center time in the open field test that are represented as bar graphs. Gray shaded area 
represents the 5 min CO2 or atmospheric air challenge, where atmospheric air was also infused 
prior to and after for 5 min (also indicated at bottom of x-axis). *, Between subjects differences 
using a Fisher’s LSD post hoc test that was protected with a repeated measures ANOVA and an 
ANOVA at each time point
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Figure 2. Line graphs indicate the effects of systemic intraperitoneal injections of 0.1 and 0.3 
mg/kg of the benzodiazepine lorazepam on 20% CO2-induced changes (from 5 min baseline) in 
(a) MAP (mm Hg), (b) HR (beats/min, BPM), (d) general locomotor activity (counts/min), and 
decreased CBT (Celsius) in freely moving rats surgically implanted with radiotelemetry probes. 
There were no significant differences in baseline MAP, HR, locomotor activity, or CBT (see 
legends on figures with baselines ± SEM). Gray shaded area represents the 5 min CO2 or 
atmospheric air challenge, where atmospheric air was also infused prior to and after for 5 min 
(also indicated at bottom of x-axis). Bar graphs indicate effects of systemic injections of 0.1 and 
0.3 mg/kg of the benzodiazepine lorazepam on 20% CO2-induced changes in (c) SI in the SI test, 
and (f) line crossings and center time in the open field test. *, Between subjects differences using 
a Fisher’s LSD post hoc test that was protected with a repeated measures ANOVA and an 
ANOVA at each time point
Johnson et al. Page 16
Depress Anxiety. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. Line graphs indicate the effects of systemic oral gavage of 30 mg/kg of DORA-12 on 
20% CO2-induced changes (from 5 min baseline) in (a) MAP (mm Hg), (b) HR (beats/min, 
BPM), (d) general locomotor activity (counts/min), and decreased CBT (Celsius) in freely 
moving rats surgically implanted with radiotelemetry probes. There were no significant 
differences in baseline MAP, HR, or CBT (see legends on figures with baselines ± SEM). 
However, there were differences noted in the baseline general locomotor activity (see baseline 
legend in Fig. 3D). Gray shaded area represents the 5 min CO2 or atmospheric air challenge, 
where atmospheric air was also infused prior to and after for 5 min (also indicated at bottom of 
x-axis). Bar graphs indicate the effects of systemic oral gavage of 30 mg/kg of DORA-12 on 20% 
CO2-induced changes in (c) SI in the SI test, and (f) line crossings and center time in the open 
field test. *, Between subjects differences using a Fisher’s LSD post hoc test that was protected 
with a repeated measures ANOVA and an ANOVA at each time point
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Figure 4. Line graphs indicate the effects of systemic intraperitoneal injections of 30 mg/kg of the 
SORA1 SB334867 on 20% CO2-induced changes (from 5 min baseline) in (a) MAP (mm Hg), (b) 
HR (beats/min, BPM), (d) general locomotor activity (counts/min), and decreased CBT (Celsius) 
in freely moving rats surgically implanted with radiotelemetry probes. There were no significant 
differences in baseline MAP, HR, locomotor activity, or CBT (see legends on figures with 
baselines ± SEM). Gray shaded area represents the 5 min CO2 or atmospheric air challenge, 
where atmospheric air was also infused prior to and after for 5 min (also indicated at bottom of 
x-axis). Bar graphs indicate the effects of systemic i.p. injections of 30 mg/kg of the SORA1 
SB334867 on 20% CO2-induced changes in (c) SI in the SI test, and (f) line crossings and center 
time in the open field test. *, Between subjects differences using a Fisher’s LSD post hoc test that 
was protected with a repeated measures ANOVA and an ANOVA at each time point
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Figure 5. Line graphs indicate the effects of systemic subcutaneous injections of 3, 10, and 30 
mg/kg of a SORA1 (compound 56: C65), on 20% CO2-induced changes (from 5 min baseline) in 
(a) MAP (mm Hg), (b) HR (beats/min, BPM), (d) general locomotor activity (counts/min), and 
decreased CBT (Celsius) in freely moving rats surgically implanted with radiotelemetry probes. 
There were no significant differences in baseline MAP, HR, locomotor activity, or CBT (see 
legends on figures with baselines ± SEM). Gray shaded area represents the 5 min CO2 or 
atmospheric air challenge, where atmospheric air was also infused prior to and after for 5 min 
(also indicated at bottom of x-axis). Bar graphs indicate the effects of systemic subcutaneous 
injections of 3,1,0 and 30 mg/kg of the SORA1 (compound A) on 20% CO2-induced changes in 
(c) SI in the SI test, and (f) line crossings and center time in the open field test. *, Between 
subjects differences using a Fisher’s LSD post hoc test that was protected with a repeated 
measures ANOVA and an ANOVA at each time point
Johnson et al. Page 19
Depress Anxiety. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 6. Line graphs indicate the effects of systemic subcutaneous injections of 10, and 30 
mg/kg of a SORA2 (JnJ10397049, on 20% CO2-induced changes (from 5 min baseline) in (a) 
MAP (mm Hg), (b) HR (beats/min, BPM), (d) general locomotor activity (counts/min), and 
decreased CBT (Celsius) in freely moving rats surgically implanted with radiotelemetry probes. 
There were no significant differences in baseline MAP, HR, locomotor activity, or CBT (see 
legends on figures with baselines ± SEM). Gray shaded area represents the 5 min CO2 or 
atmospheric air challenge, where atmospheric air was also infused prior to and after for 5 min 
(also indicated at bottom of x-axis). Bar graphs indicate the effects of systemic subcutaneous 
injections of 10 and 30 mg/kg of the SORA2 on 20% CO2-induced changes in (c) SI in the SI test, 
and (f) line crossings and center time in the open field test. *, Between subjects differences using 
a Fisher’s LSD post hoc test that was protected with a repeated measures ANOVA and an 
ANOVA at each time point
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Figure 7. Line graphs indicate the effects of repeated 20% CO2 (day 1, 3, and 5) on changes 
(from 5 min baseline) in (a) MAP (mm Hg), (b) HR (beats/min, BPM), (d) general locomotor 
activity (counts/min), and decreased CBT (Celsius) in freely moving rats surgically implanted 
with radiotelemetry probes. There were no significant differences in baseline MAP, HR, 
locomotor activity, or CBT (see legends on figures with baselines ± SEM). Gray shaded area 
represents the 5 min CO2 or atmospheric air challenge, where atmospheric air was also infused 
prior to and after for 5 min (also indicated at bottom of x-axis). Bar graphs indicate the effects of 
repeated 20% CO2-induced changes in (c) SI in the SI test, and (f) line crossings and center time 
in the open field test
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